This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Bedford Laboratories
Bedford Laboratories, a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 1992, the company has established itself as a leader in the development and manufacturing of high-quality injectable pharmaceuticals. With a focus on sterile injectable products, Bedford Laboratories serves a diverse range of healthcare providers across North America and beyond. The company is renowned for its commitment to quality and innovation, offering a comprehensive portfolio that includes generic and specialty injectable medications. Notable achievements include securing FDA approvals for numerous products, which has solidified its market position. Bedford Laboratories continues to prioritise patient safety and efficacy, making it a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Bedford Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bedford Laboratories's score of 28 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bedford Laboratories, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Hikma Pharmaceuticals PLC, which may influence its climate commitments and reporting practices. While Bedford Laboratories has not established its own reduction targets or climate pledges, it is important to note that it inherits emissions data and sustainability initiatives from its parent company, Hikma Pharmaceuticals PLC. This relationship suggests that Bedford Laboratories may align its environmental strategies with those of Hikma, which is actively engaged in climate action and sustainability efforts. As of now, Bedford Laboratories has not disclosed any specific reduction initiatives or targets, nor has it committed to the Science Based Targets initiative (SBTi). The lack of detailed emissions data and reduction commitments highlights an opportunity for Bedford Laboratories to enhance its climate strategy and transparency in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bedford Laboratories is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
